Abstract
Immunity to severe malaria is acquired quickly, operates independently of pathogen load and represents a highly effective form of disease tolerance. The mechanism that underpins tolerance in human malaria remains unknown. We developed a re-challenge model of falciparum malaria in which healthy naive adult volunteers were infected three times over a 12-month period to track the development of disease tolerance in real-time. We found that parasitaemia triggered a hardwired emergency myeloid response that led to systemic inflammation, pyrexia and hallmark symptoms of clinical malaria across the first three infections of life. In contrast, CD4+ T cell activation was quickly modified to reduce the number and diversity of effector cells upon re-challenge. Crucially, this did not silence critical helper T cell functions but instead prevented the generation of cytotoxic effectors associated with autoinflammatory disease. Tolerised hosts were thus able to prevent collateral tissue damage and injury. Host control of T cell activation can therefore be established after a single infection and in the absence of anti-parasite immunity. And furthermore, this rapid host adaptation can protect vital organs to minimise the harm caused by systemic inflammation and sequestration.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov references NCT02927145, NCT03906474, NCT03797989
Funding Statement
The VAC063 and VAC063C trials were supported in part by the Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development (USAID) under the terms of the Malaria Vaccine Development Program (MVDP) contract AID-OAA-C-15-00071, for which Leidos, Inc. is the prime contractor. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the USAID. The clinical trial was also supported in part by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The VAC069 trial was supported by funding from the European Unions Horizon 2020 research and innovation programme under grant agreement for MultiViVax (number 733073). DMS is the recipient of a Darwin Trust of Edinburgh PhD studentship. FB is the recipient of a Wellcome Trust PhD studentship (grant no. 203764/Z/16/Z). SJD held a Wellcome Trust Senior Fellowship (grant no. 106917/Z/15/Z) and is a Jenner Investigator. And PJS is the recipient of a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant no. 107668/Z/15/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The VAC063, VAC063C and VAC069 trials were sponsored by the University of Oxford. VAC063 received ethical approval from the UK NHS Research Ethics Service (Oxfordshire Research Ethics Committee A, reference 16/SC/0345) and was registered on ClinicalTrials.gov (reference NCT02927145). VAC063C received ethical approval from the UK NHS Research Ethics Service (South Central - Oxford A, reference 18/SC/0521) and was registered on ClinicalTrials.gov (reference NCT03906474). VAC069 received ethical approval from UK NHS Research Ethics Service (South Central - Hampshire A reference 18/SC/0577) and was also registered on ClinicalTrials.gov (NCT03797989). All CHMI studies were conducted in the UK at the Centre for Vaccinology and Tropical Medicine (University of Oxford) and were conducted according to the principles of the current revision of the Declaration of Helsinki 2008 and in full conformity with the ICH Guidelines for Good Clinical Practice. Volunteers signed written consent forms and consent was checked prior to each CHMI. Details of volunteer recruitment, consent, inclusion/exclusion criteria and group allocation can be found in Minassian et al., Med (NY), 2021 (PMID 34223402) for VAC063 and Minassian et al., medRxiv 2021 (doi.org/10.1101/2021.07.23.21259839) for VAC069.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All RNAseq data (whole blood and sorted T cell subsets) have been deposited in NCBIs Gene Expression Omnibus and are accessible through GEO SuperSeries accession number GSE172481. CyTOF (mass cytometry) data have been deposited at flowrepository.org and can be accessed through experiment numbers FR-FCM-Z47Z (VAC063C), FR-FCM-Z3HA (VAC069A) and FR-FCM-Z465 (VAC069B).
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE172481
